$573 Million is the total value of TRV GP III, LLC's 7 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2021 | ||||||||
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Mark Levin #1
- Kevin P. Starr #2
- Robert I. Tepper #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VOYAGER THERAPEUTICS, INC. | 22 | Q1 2023 | 74.0% |
| JOUNCE THERAPEUTICS, INC. | 20 | Q3 2022 | 24.5% |
| PLIANT THERAPEUTICS, INC. | 14 | Q3 2023 | 100.0% |
| FULCRUM THERAPEUTICS, INC. | 14 | Q4 2022 | 43.8% |
| REVOLUTION MEDICINES, INC. | 12 | Q4 2022 | 53.8% |
| DECIBEL THERAPEUTICS, INC. | 10 | Q2 2023 | 66.3% |
| NEON THERAPEUTICS, INC. | 8 | Q1 2020 | 41.1% |
| NURIX THERAPEUTICS, INC. | 8 | Q2 2022 | 17.7% |
| RELAY THERAPEUTICS, INC. | 2 | Q4 2020 | 37.7% |
| MYOKARDIA, INC. | 2 | Q1 2018 | 22.1% |
View TRV GP III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 4 | 2023-02-06 |
| 4 | 2023-02-01 |
| 4 | 2023-01-31 |
| 4 | 2023-01-26 |
| 4 | 2023-01-24 |
View TRV GP III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.